J. Dijoseph, G. N. Mir
Feb 1, 1986
Citations
1
Influential Citations
2
Citations
Quality indicators
Journal
Drug Development Research
Abstract
Lidamidine is a new, nonnarcotic, nonanticholinergic drug intended for the treatment of diarrhea. In preclinical test models, it compares favorably in both potency and duration of action with marketed antidiarrheal drugs. Lidamidine's intestinal antisecretory effects are mediated through the activation of peripheral alpha‐2 adrenoceptors. Lidamidine crosses the blood brain barrier poorly and is therefore devoid of the centrally mediated alpha‐2 effects that have limited the use of other alpha‐2 adrenoceptor agonists in the intestinal tract. Lidamidine relaxes circular and longitudinal smooth muscle in the intestinal tract and may be useful for treatment of certain intestinal motility disorders. In clinical trials, lidamidine has proven to be effective for the management of diarrheal diseases.